Literature DB >> 10923273

Administration of recombinant follicle stimulating hormone in a woman with allergic reaction to menotropin: a case report.

S Harrison1, T Wolf, M I Abuzeid.   

Abstract

This report describes a patient who experienced a generalized allergic reaction to Pergonal during controlled ovarian hyperstimulation in preparation for an intracytoplasmic sperm injection procedure for treatment of severe male factor infertility. The report describes a successful desensitization protocol which allowed the patient to complete her treatment cycle despite the allergic reaction to Pergonal. Subsequently recombinant follicle stimulating hormone was used successfully in inducing follicular growth in the absence of any allergic reactions. Therefore, this report confirms other studies which have suggested that an allergic reaction to human menopausal gonadotropins is due to impurities in such urine-derived products.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923273     DOI: 10.3109/09513590009167674

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  A prospective, randomized and blinded comparison between 10,000 IU urinary and 250 microg recombinant human chorionic gonadotropin for oocyte maturation in in vitro fertilization cycles.

Authors:  Vicente Abdelmassih; Flavio G Oliveira; Sergio P Goncalves; Adriana D Varella; Michael P Diamond; Roger Abdelmassih
Journal:  J Assist Reprod Genet       Date:  2005-04       Impact factor: 3.412

2.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

Review 3.  Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis.

Authors:  Philippe Lehert; Joan C Schertz; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2010-09-16       Impact factor: 5.211

4.  Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.

Authors:  Peter Sydow; Norbert Gmeinwieser; Katrin Pribbernow; Christoph Keck; Inka Wiegratz
Journal:  Reprod Biol Endocrinol       Date:  2020-05-26       Impact factor: 5.211

5.  Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women.

Authors:  Andreas Lammerich; Peter Bias; Beate Gertz
Journal:  Int J Womens Health       Date:  2015-07-16

6.  Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.

Authors:  Thomas Strowitzki; Waldemar Kuczynski; Arnd Mueller; Peter Bias
Journal:  Reprod Biol Endocrinol       Date:  2016-06-10       Impact factor: 5.211

7.  Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).

Authors:  Thomas Strowitzki; Waldemar Kuczynski; Arnd Mueller; Peter Bias
Journal:  Reprod Biol Endocrinol       Date:  2016-01-06       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.